[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cognitive-symptoms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cognitive-symptoms":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,84,113],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100627815","cranberry-polyphenols-and-stress-resilience-during-multitasking-in-healthy-adults-100627815",false,"NCT07453537","Cranberry Polyphenols and Stress Resilience During Multitasking in Healthy Adults","Cranberry Polyphenols and Human Stress Resilience: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Integrating Cognitive, Physiological, and Microbiome Adaptations Underlying Nutritional Neuroprotection and Multitasking Performance in Healthy Adults.","CRAN-MULTI","Inclusion Criteria:\n\n* At least 110 pounds\n* Between 30 and 55 years\n* BMI between 18.9 and 29.9 kg\u002Fm²\n* A minimum education level of high school or above\n\nExclusion Criteria:\n\n* Heavy caffeine users (consuming more than 300 mg\u002Fday or more than two cups of coffee per day)\n* Alcohol consumption exceeding three drinks per week\n* A smoking history of 10 years or more, or current use of cannabis products\n* Uncontrolled hypertension\n* Clinically diagnosed illnesses such as diabetes, cardiovascular disease, neurological disorders, or mental health conditions\n* Participants currently taking prescribed anti-inflammatory medications, antibiotics, or antidepressants that may affect study outcomes, particularly those related to blood and fecal sample analysis\n* Individuals who regularly take vitamin or mineral supplements and are unwilling to discontinue them for the duration of the study will not qualify.\n* Participants must be willing to maintain their current daily routine and lifestyle, undergo body weight and height measurements, and notify study coordinators of any illnesses or significant adverse life events during the study period\n* Those with specific dietary restrictions that prevent them from consuming the standardized breakfast sandwich required in the study protocol\n* Participants must successfully complete the on-site multitasking task as a screening measure prior to signing consent.\n* Beck's Depression Inventory score of 21 or higher\n* Beck's Anxiety Inventory score of 21 or higher\n* A history of severe suicidal tendencies, or seasonal depression\n* Pregnancy and breastfeeding (Female participants must complete four pregnancy tests throughout the study and track their menstrual cycle. Those unwilling to comply with these requirements will not be eligible.)\n* Potential participants must not have taken any anti-inflammatory medications, antibiotics, or antidepressants within the past three months prior to the start of the study\n* Individuals who were previously enrolled in IRB#202300950 will be excluded due to the learning effect of cognitive tests, ensuring accurate data collection for this study",true,"ALL","30 Years","55 Years",{"count":22,"type":23},84,"ESTIMATED","INTERVENTIONAL",[26],"NA","This randomized, double-blind, placebo-controlled clinical trial evaluates whether 70 days of daily cranberry juice consumption improves cognitive performance and motor accuracy and reduces psychological and physiological stress responses during a motor-cognitive dual-task multitasking challenge in healthy adults aged 30-55 (Aim 1). It is hypothesized that chronic cranberry juice intake will enhance dual-task performance and attenuate stress reactivity (Hypothesis 1). It is further hypothesized that cranberry juice will mitigate multitasking-related fatigue, mood fluctuations, and cognitive impairment, accompanied by favorable changes in circulating stress biomarkers and stress-regulatory neurochemical pathways (Aim 2\u002FHypothesis 2). Finally, the study incorporates gut analysis to determine whether cranberry juice induces beneficial shifts in the gut microbiota and microbial metabolites (e.g., SCFAs) and whether these changes are associated with improved cognitive and stress-related outcomes, consistent with a microbiome-gut-brain axis mechanism (Aim 3\u002FHypothesis 3).",[29,30,31,32,33,34],"Stress Response","Mental Stress","Multitasking Behavior and Multitasking Ability","Physiological Stress","Cognitive Symptoms","Motor Activity","RECRUITING","2026-06-29",{"date":38,"type":39},"2026-06-30","ACTUAL",{"date":41,"type":23},"2026-08-01",{"date":43,"type":23},"2029-08-01",{"name":45,"class":46},"University of Florida","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":18,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":24,"phases":57,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":47},"100633483","cognitive-enhancement-in-recurrent-depression-the-cog-d-r-study-100633483","NCT07527273","Cognitive Enhancement in Recurrent Depression (The COG-D-R Study)","Inclusion Criteria:\n\n* Age \\> 60 years\n* Evidence of executive dysfunction via SUBJECTIVE COMPLAINTS (At least one subdomain of the Behavior Rating Inventory of Executive Function in Adults (BRIEF-A) at T \\> 65, or At least one average score of \\> 1.5 on Planning, Organization, or Attention subdomains of the Everyday Cognition Scale (ECog)) or OBJECTIVE PERFORMANCE (At least one demographically adjusted z-score \\> -1.0 SD below the mean on a measure of executive functioning (Digits backward, Trails B, or total Verbal Fluency) on the National Alzheimer's Coordinating Center (NACC) Uniform Data Set 3.0).\n* DSM-5 diagnosis of a current or past (within last 3 years) depressive episode (e.g., Major Depressive Disorder (MDD), Persistent Depressive Disorder (PDD)) via the using the Structured Clinical Interview for DSM-5 Disorders (SCID-5).\n* Presence of 2 or more lifetime depressive episodes to be considered \"recurrent.\"\n* Either stable antidepressant regimen for at least 6 weeks or no current antidepressant treatment (no plans to change treatment over course of study).\n* Fluent in English\n\nExclusion Criteria:\n\n* Other psychiatric conditions via the SCID-5 (including history of bipolar disorder and psychosis, excluding comorbid anxiety disorders)\n* Severe depression (MADRS score \\> 29)\n* Acute suicidality on clinical evaluation by study clinician and via response on MADRS item 10 (score of 4 or more would require further assessment)\n* Acute grief (occurring within past month)\n* History of alcohol use disorder or substance use disorder of moderate or greater severity in the last 12 months\n* Medications that would significantly interfere with tDCS effects (i.e., sodium channel blockers, GABA-ergic or glutamatergic drugs; see Appendix B for exclusionary list)40\n* Primary neurological disorder (e.g., epilepsy, brain tumor, Parkinson's disease, Alzheimer's disease, dementia diagnosis)\n* Montreal Cognitive Assessment (MoCA) \\\u003C 23\n* Primary amnestic cognitive profile (\\>1.5 SD below demographically-adjusted mean on NACC memory measures in context otherwise normal cognitive profile, or per clinician judgement)\n* Any physical or intellectual disability affecting ability to complete assessments\n* Unstable medical illness needing urgent treatment\n* MRI contraindications\n* Electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) in last 2 months\n* Current involvement in psychotherapy\n* Current involvement in other research studies (including but not limited to: neuromodulation \\[TMS or tDCS\\] or investigational drug studies). Observational studies \\[without intervention\\] are acceptable.","60 Years",{"count":56,"type":23},69,[26],"The goal of this clinical trial is to learn if a combination of non-drug treatments works to benefit memory, thinking, and brain functioning in older individuals with recurrent depression. The non-drug approaches the investigators are studying include transcranial direct current stimulation (tDCS) and computerized cognitive training. tDCS uses small currents of electricity on the forehead to potentially stimulate your brain's ability to process and learn. Computerized cognitive training uses tablet games to improve memory and thinking.\n\nIn this study, two different cognitive training programs are being investigated, both of which are stimulating and designed to engage brain activity. One that is believed to be a specific treatment for depression, while the other provides extra stimulation for the brain that is non-specific. Two different tDCS parameters - active stimulation and sham (or placebo) stimulation - are also being investigated.\n\nParticipants will be randomized to one of three study groups:\n\n1. Depression cognitive training treatment with active brain stimulation\n2. Depression cognitive training treatment with sham brain stimulation\n3. Non-specific cognitive training treatment with sham brain stimulation\n\nThe main questions this clinical trial aims to answer are:\n\n* Does \"depression cognitive training treatment with active brain stimulation\" benefit thinking and memory more so than the other treatments?\n* Does \"depression cognitive training treatment with active brain stimulation\" benefit brain functioning more so than the other treatments?\n\nParticipants will:\n\n* Complete several baseline and post-intervention visits at the research center for checkups and tests over the course of 3-4 months.\n* Visit the research center daily for 4 weeks to complete their assigned treatment.",[60,61,33],"Aging","Depression",[63,64,65,66,67,68,69,70,71,72,73],"geriatrics","aging","elderly","cognition","memory","thinking","depression","tDCS","cognitive training","cognitive remediation","digital therapeutics","NOT_YET_RECRUITING","2026-05-12",{"date":77,"type":39},"2026-05-15",{"date":79,"type":23},"2026-09-01",{"date":81,"type":23},"2028-06-30",{"name":83,"class":46},"Vanderbilt University Medical Center",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":18,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":24,"phases":95,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":47},"100580575","cognitive-rehabilitation-for-refugees-with-traumatic-brain-injury-and-cognitive-impairment-100580575","NCT06839079","Cognitive Rehabilitation for Refugees With Traumatic Brain Injury and Cognitive Impairment","Feasibility RCT of an Adapted Cognitive Rehabilitation Program for Refugees and Asylum Seekers With TBI and Cognitive Impairment","Inclusion Criteria:\n\n1. Identify as an asylum seeker, refugee or have been granted asylum or other form of humanitarian relief.\n2. Mild or moderate TBI sustained after the age of 18\n3. Age 18-65\n4. Subjective cognitive impairment\n5. English or Spanish language proficiency\n6. Ability to provide verbal informed consent\n7. Ability and willingness to answer questionnaires and participation in the Intervention\n\nExclusion Criteria:\n\n1. Participation in cognitive rehabilitation treatment current or in past 3 months\n2. Severe TBI or TBI only sustained under the age of 18\n3. Diagnosis of bipolar, psychosis, active substance use, self-reported current active suicidal ideation or plan (Potential participants can be screened again after 30 days in the case of suicidal ideation)","18 Years","65 Years",{"count":94,"type":23},50,[26],"Researchers at Massachusetts General Hospital are looking to see if a program created to help improve thinking and memory can work for refugees with traumatic brain injury (TBI). They're checking if this program is practical and if people find it helpful.\n\nThe study will have two groups. Participants will complete a first questionnaire and then be assigned to a group by chance. One group will participate in the program immediately and then answer the second questionnaire (approximately 3 months after the first questionnaire they did). Then they will wait and then answer the third and final questionnaire approximately 6 months after the first one.\n\nThe second group will wait and answer the second questionnaire approximately 3 months after the first one. Then they will receive the program and answer the third and final questionnaire (approximately 6 months after the first one they did.)",[98,33],"TBI (Traumatic Brain Injury)",[100,101,102,103],"Traumatic Brain Injury","Cognition","Refugees","Asylum Seekers","2026-03-08",{"date":106,"type":39},"2026-03-11",{"date":108,"type":39},"2025-10-15",{"date":110,"type":23},"2027-12",{"name":112,"class":46},"Massachusetts General Hospital",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":18,"minAge":91,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":24,"phases":123,"briefSummary":124,"conditions":125,"keywords":128,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":4},"100623194","pqq-for-cognitive-and-negative-symptoms-100623194","NCT07393464","PQQ for Cognitive and Negative Symptoms","The Efficacy and Safety of Pyrroloquinoline Quinone add-on Treatment for Negative and Cognitive Symptoms in Chronic Schizophrenia","Inclusion criteria:\n\nEligible male and female patients aged 18 to 50 years, diagnosed with schizophrenia according to the criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5), will be included in the study. Participants are required to meet the following criteria: a Positive and Negative Syndrome Scale (PANSS) total scores of ≥ 60 (indicating an active phase of the illness), a PANSS negative subscale scores of ≥ 20, and a duration of illness of at least 2 years (indicating chronic schizophrenia). Additionally, participants must have been on a stable dose of antipsychotic medication for a minimum of 6 weeks prior to enrollment, and the use of antioxidants or anti-inflammatory medications is prohibited within 2 weeks preceding enrollment.\n\nExclusion criteria:\n\nPatients with comorbid psychiatric disorders as defined by the DSM-5, such as substance abuse or dependence (excluding nicotine), or intellectual disability (IQ \\\u003C 70); those with significant depressive symptoms, defined as a score ≥14 on the 17-item Hamilton Depression Rating Scale (HAMD-17) or ≥ 4 on the depression item of PANSS; individuals with severe medical or neurological conditions, or those unable to communicate effectively; patients with a known allergy to PQQ disodium salt, or who are pregnant, breastfeeding, or have severe hepatic or renal impairment; women of childbearing potential who are not using reliable contraception; patients who have received modified electroconvulsive therapy (MECT) or other physical treatments within six months prior to enrollment; and those currently receiving treatments that cannot be discontinued, including antidepressants, mood stabilizers, antihistamines, or combination therapy with two or more antipsychotics (except for low-dose aripiprazole, ≤ 5 mg\u002Fday, used solely for prolactin reduction).\n\nAdditional exclusion criteria for participants undergoing fMRI scanning:\n\nParticipants are required to complete a comprehensive safety questionnaire addressing potential risks associated with exposure to a 3-Tesla magnetic field and the MRI environment. MRI-specific exclusion criteria include: the presence of MRI-incompatible implants (e.g., cochlear implants, insulin pumps, pacemakers, or other metallic implants); a history of possible intraocular metallic foreign bodies due to manual labor without appropriate eye protection; tattoos containing red pigments; claustrophobia; or unwillingness to be informed of any incidental structural brain abnormalities detected during the scan.","50 Years",{"count":122,"type":23},70,[26],"Schizophrenia is a complex mental disorder characterized by a range of symptoms, including negative symptoms and cognitive impairments. Recent research has indicated the potential benefits of targeting mitochondrial dysfunction, oxidative stress, and inflammatory responses in alleviating symptoms of schizophrenia. However, the results remain inconsistent across various studies. This study aims to evaluate the efficacy of Pyrroloquinoline quinone (PQQ) in reducing negative symptoms and improving cognitive function in patients with chronic schizophrenia. The investigation will focus on changes in severity scores from baseline to endpoint, as well as during an eight-week follow-up period. A double-blind, randomized controlled trial will be conducted involving participants diagnosed with chronic schizophrenia. Participants will be randomly assigned to receive either PQQ or a matched placebo. Data will be collected through questionnaires and neuroimaging techniques, including resting-state scans and multimodal tasks to assess functional connectivity and activation in target brain regions. Statistical analyses will include descriptive statistics, voxel-by-voxel multiple regression, and linear mixed models to account for repeated measurements. Additionally, potential moderating effects of demographic factors such as age and gender will be examined using ANCOVAs. The study will also monitor adverse events and ensure participant safety through a rigorous reporting and unblinding procedure. It is hope to provide insights into the therapeutic potential of PQQ in managing schizophrenia symptoms, contributing to the development of more effective treatment strategies for this challenging condition.",[126,33,127],"Schizophrenia","Negative Symptoms",[129,130,131,132,133],"cognitive symptom","negative symptom","schizophrenia","Pyrroloquinoline Quinone","MCCB","2026-02-06",{"date":136,"type":39},"2026-02-10",{"date":138,"type":23},"2026-02-15",{"date":140,"type":23},"2028-04-15",{"name":142,"class":46},"Tianjin Anding Hospital"]